Don't miss tomorrow's biopharma industry news
Let BioPharma Dive's free newsletter keep you informed, straight from your inbox.
By signing up to receive our newsletter, you agree to our
. You can unsubscribe at anytime.
Novo Nordisk’s weight loss pill approved by FDA
The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase of an escalating battle for control of the obesity drug market.
The Food and Drug Administration approved an oral version of Novo Nordisk's weight loss pill Wegovy on Dec. 22, 2025.
The Food and Drug Administration on Monday
of Novo Nordisk’s weight loss medication Wegovy, setting off the next phase of a high-stakes battle with rival Eli Lilly for control of the lucrative obesity drug market.
The approval marks a paradigm shift in obesity treatment. The market is currently dominated by weekly injections that can spur significant weight loss. The pill forms of those drugs appear to be somewhat less potent, but are more convenient to take and could substantially broaden use. Combined, injectable and oral drugs from this “GLP-1” class are
expected by Wall Street analysts to generate annual sales of more than 00 billion
Novo will have a head start with oral Wegovy, which will be launched in early January. But it could be joined swiftly by Eli Lilly’s experimental pill orforglipron, which succeeded in late-stage testing this year and may be approved within weeks
thanks to a “national priority” voucher
“The pill is here,” said Novo CEO Mike Doustdar in a statement. “No other current oral GLP-1 treatment can match the weight loss delivered by the Wegovy pill, and we are very excited for what this will mean for patients in the U.S.”
Pressured by President Trump, the FDA and other federal health agencies have intensely focused on expanding the number of available obesity medications as well as access to them. Novo and Lilly also reached deals with the White House to cut the prices of their medications for some Medicare beneficiaries and those willing to pay cash. As part of those negotiations, they pledged to price the starter doses of their oral drugs at 49 a month, too.
For Novo, the arrival of oral Wegovy comes after a series of setbacks that have depressed its share price and seen the company lose its leading position to Lilly. It’s also the result of a strategic shift. The Wegovy pill, a higher-dose version of an oral GLP-1 it sells as Rybelsus for diabetes,
successfully concluded multiple Phase 3 trials in 2023
. But Novo sidelined regulatory submissions at the time as it struggled to meet the surging demand for GLP-1 drugs.
experimental dual-acting injectable drug
generate disappointing study data. Though that dual-acting drug, CagriSema, has since been submitted to regulators, Novo has also accumulated more data for oral Wegovy and
Novo’s Phase 3 trials, called OASIS, tested oral Wegovy at doses reaching 50 milligrams a day. The last to report results, OASIS-4, showed that the 25 milligram dose approved Monday helped people with obesity or are overweight and have related health complications
lose an average of 14% of their body weight
over 71 weeks, or 17% in those who fully adhered to treatment plans.
Over the course of a week, seven 25 milligram daily doses of a Wegovy pill would amount to more than 50 times the 2.4 milligrams packed into the highest-dose weekly injection. That difference is necessitated by the
difficulty of delivering a peptide drug
like Wegovy through the digestive system.
By comparison, orforglipron is a chemical, or “small molecule,” drug, which requires less complex manufacturing. In clinical trials, the
highest daily dose tested was 36 milligrams
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
By signing up to receive our newsletter, you agree to our
. You can unsubscribe at anytime.
A valid email address is required.
Please select at least one newsletter.
Drugs from China are reshaping biotech. Track the licensing deals here.
U.S. and European companies announced at least 62 drug licensing deals with Chinese companies in 2025, the largest five of which topped billion in overall value.
Adeline Kon / BioPharma Dive/BioPharma Dive
Drug patents protect pharma profits. Track when they’ll expire.
AbbVie reached legal settlements delaying the arrival of generic versions of Rinvoq until 2037, enabling four more years of exclusivity for a drug that banked about billion in sales in 2024.
Keep up with the story. Subscribe to the BioPharma Dive free daily newsletter
By signing up to receive our newsletter, you agree to our
. You can unsubscribe at anytime.
A valid email address is required.
Please select at least one newsletter.
Subscribe to BioPharma Dive for top news, trends & analysis
By signing up to receive our newsletter, you agree to our
. You can unsubscribe at anytime.
A valid email address is required.
Please select at least one newsletter.
Biopharma climbs higher as 9 drugmakers ink ‘pandering’ drug price deals with Trump
Cytokinetics set to battle Bristol Myers as FDA approves heart drug
Radiopharmaceutical specialist Aktis seeks an IPO
Patient deaths put Merck, Daiichi’s ADC trial on partial hold
The Evolution of Outsourced Buffer Production in Manufacturing
How to Unlock A Successful ICH E6(R3) Implementation
Successful Biomarker-Driven Cancer Drug Development
Will NIH’s new director reform his agency—or destroy it?
Your Brain Ages in Five Distinct Stages, New Research Shows
Revolutionizing Next Generation Gene Therapies with On-Demand Large DNA Construct Synthesis and Novel, Designable Delivery Vehicles
Provided by Ansa Biotechnologies
Developing an Array of Diverse Vaccine Platforms
Provided by BioPharma Dive's studioID; Sponsored content by Novavax in partnership with studioID
2026 Life Sciences AI & Data Predictions
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
By signing up to receive our newsletter, you agree to our
. You can unsubscribe at anytime.
A valid email address is required.
Please select at least one newsletter.
ProPharma Expands Operations with New Office in Hyderabad
Sedulo Group Releases 2025 Life Sciences Competitive Intelligence Survey Report, Highlighting …
SVD to auction off high end biotech assets from Fellow and Solve FSHD in Let'sGoCure Online Au…
From Silicon Valley Disposition
The Next Chapter in Obesity Therapeutics: Vial’s INHBE siRNA Draws KOL Praise as a Next‑Genera…
Drugs from China are reshaping biotech. Track the licensing deals here.
U.S. and European companies announced at least 62 drug licensing deals with Chinese companies in 2025, the largest five of which topped billion in overall value.
Adeline Kon / BioPharma Dive/BioPharma Dive
Drug patents protect pharma profits. Track when they’ll expire.
AbbVie reached legal settlements delaying the arrival of generic versions of Rinvoq until 2037, enabling four more years of exclusivity for a drug that banked about billion in sales in 2024.
Novo Nordisk’s weight loss pill approved by FDA
Biopharma CEO optimism is wavering in the US
Biopharma climbs higher as 9 drugmakers ink ‘pandering’ drug price deals with Trump
Novo files for CagriSema approval; Merck and Pfizer’s trial win
Industry Dive is an Informa TechTarget business.
© 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. | View our
Cookie Preferences / Do Not Sell
This website is owned and operated by Informa TechTarget, part of a global network that informs, influences and connects the world's technology buyers and sellers. All copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. TechTarget, Inc.'s registered office is 275 Grove St. Newton, MA 024